{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-284214","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.207774+00:00","generated_at":"2026-05-28T23:39:09.572128+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Sanofi terminates losmapimod deal; Fulcrum loses up to $975M in milestones","bullets":["Sanofi terminated for convenience the May 2024 collaboration for losmapimod (FSHD) effective April 17, 2025.","Fulcrum received $80M upfront but forfeits all remaining milestones (up to $975M) and tiered royalties.","Fulcrum no longer entitled to global development cost reimbursement; Phase 3 trial obligations continue until termination.","After termination, Fulcrum retains full rights to losmapimod but loses ex-U.S. partner and future payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-284214","json":"https://secwatch.observer/filing/0001193125-24-284214.json","markdown":"https://secwatch.observer/filing/0001193125-24-284214.md","text":"https://secwatch.observer/filing/0001193125-24-284214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524284214/0001193125-24-284214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524284214/d911298d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:39:09.572128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}